October, 2025
October 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Christopher Cannon on Evolocumab – Landmark Phase 3 Trial Shows Benefit in Those at High Risk of CV Events
Oct 3, 2025, 11:50

Christopher Cannon on Evolocumab – Landmark Phase 3 Trial Shows Benefit in Those at High Risk of CV Events

Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, shared on LinkedIn:

”Late-breaking news!!!

PCSK9 inhibition with evolocumab shows benefit in those at high risk of CV events, (in addition to secondary prevention as shown in FOURIER)”

Read the full article here.

Article: Landmark Phase 3 Trial (Vesalius-CV) Meets Primary Endpoints in a Cardiovascular Primary Prevention Study of 12,000 Patients

Christopher Cannon on Evolocumab - Landmark Phase 3 Trial Shows Benefit in Those at High Risk of CV Events

Stay updated on the latest scientific breakthroughs with Hemostasis Today.